Cardioplegia Solution Recalled Nationwide for Sterility Assurance Concerns
Central Admixture Pharmacy Services recalls 613 bags of cardioplegia solution nationwide due to FDA inspection concerns about sterility assurance.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall where sterility assurance has been called into question by FDA inspection, representing a risk-of-harm to patients. However, no illnesses or injuries have been reported, and the hazard is theoretical rather than confirmed contamination.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling Cardioplegia Solution, Induction 4:1 Plasma-Lyte/Tromethamine, High Potassium. The product is a 500 mL sterile injectable solution distributed nationwide.
An FDA inspection called into question the sterility assurance of these products. Lack of adequate sterility assurance means the product may not meet pharmaceutical standards for sterility and safety.
The recall affects 613 bags with the following lot numbers and expiration dates: Lot 37-894299 (Exp 04/29/2023), Lot 37-897051 (Exp 05/11/2023), Lot 37-897368 (Exp 05/12/2023), Lot 37-898794 (Exp 05/18/2023), Lot 37-899614 (Exp 05/20/2023), and Lot 37-900608 (Exp 05/25/2023). The product was distributed nationwide.
Hospitals and healthcare facilities that received this product should check their inventory for affected lot numbers. Anyone with questions about this recall should contact the recalling firm or the FDA.
The recalled product
- Product
- Cardioplegia Solution, Induction 4:1 Plasma-Lyte/Tromethamine, High Potassium, packaged in 500 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., Lehigh Valley, 6580 Snowdrift Road, Allentown, PA 18106, NDC 71285-0111-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Cardioplegia
- Affected units
- 613
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (12)
- Lot # 37-894299
- Exp 04/29/2023
- 37-897051
- Exp 05/11/2023
- 37-897368
- Exp 05/12/2023
- 37-898794
- Exp 05/18/2023
- 37-899614
- Exp 05/20/2023
- 37-900608
- Exp 05/25/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 108 recalled by Central Admixture Pharmacy Services, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 108 products in this recall →Related recalls
Same manufacturer · Central Admixture Pharmacy Services, Inc.
See all →- ModeratePediatric TPN Bags Recalled for Incorrect Formulation
FDA (Drugs) · 2026-08-12
- SeverePediatric Total Parenteral Nutrition Bag Recalled for Incorrect Formulation
FDA (Drugs) · 2026-07-01
- SevereInjectable Phenylephrine Solution Recalled Due to Particulate Matter Contamination
FDA (Drugs) · 2025-03-19
- HighInjectable Lidocaine Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- HighMidazolam Injectable Solution Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2023-10-11
Same hazard · lack of sterility
See all →- HighRohto Cooling Eye Drops Max Strength Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15